Covagen's drug development platform
Covagen's proprietary platform technology enables the isolation of high affinity protein-based binders called Fynomers, which can potentially change the activity of target molecules relevant in various diseases. Moreover, Fynomers could be suitable as vehicles for the targeted delivery of bioactive molecules to sites of diseases such as cancer.
Fynomers are derived from the novel, fully human protein scaffold Fyn SH3, which has highly attractive properties, rendering this domain a very promising starting point for the development of next generation protein drugs.
